Cognitive enhancement as a pharmacotherapy target for stimulant addiction
Effectiveness bank home page. Opens new windowReview analysis

This entry is our analysis of a review or synthesis of research findings added to the Effectiveness Bank. The original review was not published by Findings; click Title to order a copy. Free reprints may be available from the authors – click prepared e-mail. The summary conveys the findings and views expressed in the review.

Links to other documents. Hover over for notes. Click to highlight passage referred to. Unfold extra text Unfold supplementary text
Copy title and link | Comment/query |

Cognitive enhancement as a pharmacotherapy target for stimulant addiction.

Sofuoglu M.
Addiction: 2010, 105, p. 38–48.
Unable to obtain a copy by clicking title? Try asking the author for a reprint by adapting this prepared e-mail or by writing to Dr Sofuoglu at You could also try this alternative source.

Extends the search for an effective drug-based treatment for stimulant dependence to 'cognitive enhancers' which can redress associated deficits in the ability to perform tasks requiring attention, memory or other self-control or intellectual abilities.

Summary Background No medications have been proven to be effective for cocaine and methamphetamine addiction. Attenuation of drug reward has been the main strategy for medications development, but this approach has not led to effective treatments. Thus, there is a need to identify novel treatment targets in addition to the brain reward system.

Aim To propose a novel treatment strategy for stimulant addiction that will focus on medications enhancing cognitive function and attenuating drug reward.

Methods Pre-clinical and clinical literature on potential use of cognitive enhancers for stimulant addiction pharmacotherapy was reviewed.

Results and conclusions Cocaine and methamphetamine users show significant cognitive impairments, especially in attention, working memory and response inhibition functions. The cognitive impairments seem to be predictive of poor treatment retention and outcome. Medications targeting acetylcholine and norepinephrine are particularly well suited for enhancing cognitive function in stimulant users. Many cholinergic and noradrenergic medications are on the market and have a good safety profile and low abuse potential. These include galantamine, donepezil and rivastigmine (cholinesterase inhibitors), varenicline (partial nicotine agonist), guanfacine (alpha2-adrenergic agonist) and atomoxetine (norepinephrine transporter inhibitor). Future clinical studies designed optimally to measure cognitive function as well as drug use behaviour would be needed to test the efficacy of these cognitive enhancers for stimulant addiction.

Last revised 20 December 2010

Open Effectiveness Bank home page

Top 10 most closely related documents on this site. For more try a subject or free text search

REVIEW 2008 The search for medications to treat stimulant dependence

REVIEW 2012 BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

REVIEW 2009 Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials

REVIEW 2006 Antidepressants curb depression but add little to strong 'talking therapies'

REVIEW 2018 A review of brain stimulation methods to treat substance use disorders

STUDY 2012 Double-blind placebo-controlled evaluation of the PROMETATM protocol for methamphetamine dependence

REVIEW 2016 How can contingency management support treatment for substance use disorders? A systematic review

STUDY 2010 Review of treatment for cocaine dependence

STUDY 2015 A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence

STUDY 2001 Antabuse reduces cocaine and alcohol use among opiate maintenance patients